Health Care • Biotechnology: Pharmaceutical Preparations
$38.59 ▲ +0.09
(+0.23%)
MKT CAP: $2.25B • VOL: 778.9K
52W L $26 52W H $43
HRMY // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $868.5M | $714.7M | $582.0M |
| YoY Revenue Growth % | +21.5% | +22.8% | — |
| Gross Profit | $670.1M | $557.9M | — |
| Gross Margin % | 77.2% | 78.1% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $208.5M | $190.8M | $192.0M |
| Operating Margin % | 24.0% | 26.7% | 33.0% |
| Net Income (GAAP) | $158.7M | $145.5M | $128.9M |
| EBITDA (Normalized) | $208.7M | $191.7M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $348.2M | $219.8M | $219.4M |
| Capital Expenditures (CapEx) | $310.0K | $1.2M | — |
| Free Cash Flow (FCF) | $347.9M | $218.7M | $219.4M |
| FCF Margin % | 40.1% | 30.6% | 37.7% |
| Return on Invested Capital (ROIC %) | 63.0% | 40.8% | — |
| Cash & Short-Term Equivalents | $752.5M | $453.0M | — |
| Total Debt (Short + Long Term) | $143.7M | $163.0M | — |
| Total Stockholders' Equity | $870.2M | $659.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR HRMY.